Gilead(US:GILD) Jin Rong Jie·2025-08-08 13:49Core Insights - Gilead Sciences (GILD) opened with a 5.05% increase on August 8, reaching $115.845 per share, with a trading volume of $34.6124 million and a total market capitalization of $143.741 billion [1][2]. Financial Performance - As of June 30, 2025, Gilead Sciences reported total revenue of $13.749 billion, reflecting a year-over-year growth of 0.8% [1]. - The company achieved a net profit attributable to shareholders of $3.275 billion, which represents a significant year-over-year increase of 228.13% [1]. Share Buyback Activity - On August 7, Gilead Sciences announced a cumulative share repurchase amounting to $1.257 billion for the second quarter of 2025 [2]. Company Overview - Gilead Sciences is a research-based biopharmaceutical company focused on discovering and addressing unmet medical needs through the development and commercialization of innovative drugs [2]. - The company's product portfolio and research pipeline include treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, as well as cardiovascular diseases [2].